Overview
Title
To reauthorize the congenital heart disease research, surveillance, and awareness program of the Centers for Disease Control and Prevention, and for other purposes.
ELI5 AI
S. 3757 is a bill that helps doctors and scientists learn more about heart problems in babies by having meetings and writing reports on what they find out. It extends the time for these activities from 2025 to 2029 so that they can continue their important work.
Summary AI
S. 3757 aims to reauthorize the program for congenital heart disease research, surveillance, and awareness at the Centers for Disease Control and Prevention. The bill mandates a workshop within a year of enactment to identify research gaps and workforce issues related to the lifelong needs of patients with congenital heart disease. It also requires a report within three years about strategies to advance research and address provider shortages. Additionally, it extends certain program authorizations from 2025 through 2029.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
The "Congenital Heart Futures Reauthorization Act of 2024" aims to continue federal efforts in addressing the lifelong impacts of congenital heart disease through research, surveillance, and awareness under the Centers for Disease Control and Prevention (CDC). This bill, formally known as S. 3757, seeks to extend the work initiated in previous legislation, ensuring that ongoing research and resource allocation support the needs of adults living with congenital heart disease.
Summary of the Bill
The bill proposes several key actions: organizing a workshop with experts to identify research gaps, addressing workforce capacity shortages for healthcare providers treating adult congenital heart disease patients, and fostering collaboration among stakeholders. Additionally, the Secretary of Health and Human Services is required to report to Congress, within three years, on the progress and findings related to these initiatives. The funding authorization period is also extended from 2025 through 2029.
Significant Issues
One major concern with the bill is the absence of specified budgetary allocations for the proposed activities, such as the workshop and subsequent report. Without clear financial guidelines, there may be risks of inefficient spending. Moreover, the criteria for selecting stakeholders and experts involved in these efforts are vaguely defined, potentially leading to unbalanced stakeholder representation. The timeline for delivering the report to Congress, set at three years after enactment, could delay addressing urgent needs. Furthermore, the bill lacks a definitive framework for evaluating the effectiveness of its recommendations, which could result in inadequate accountability. Lastly, the bill does not provide an explanation for extending the funding period, raising questions about the rationale for this decision.
Broad Public Impact
For the general public, particularly individuals and families affected by congenital heart disease, this bill represents a continuation of federal support aimed at improving health outcomes and quality of life. It underscores a long-term commitment to understanding and addressing the complexities of congenital heart disease across the lifespan, potentially leading to better treatment options and healthcare accessibility.
Impact on Stakeholders
Healthcare providers and researchers specializing in congenital heart disease stand to benefit from enhanced collaboration and potentially increased resources resulting from the bill. However, the lack of clarity around funding and workshop composition might create uncertainty and affect stakeholder engagement. Adult patients with congenital heart disease could see improved access to care as strategies to address workforce shortages are developed. On the other hand, if the bill fails to deliver on its outlined strategies effectively, these individuals could experience ongoing challenges in accessing appropriate care.
Overall, while the Congenital Heart Futures Reauthorization Act of 2024 proposes a promising continuation of support for congenital heart disease research and care, the success of its implementation will heavily rely on resolving the identified issues and ensuring that all stakeholders are effectively engaged.
Issues
The bill does not specify the budget or funding allocated for the stakeholder workshop and report, potentially leading to financial oversight concerns and possible wasteful spending. This issue is found in Section 2.
The timeline for issuing the report is three years after the enactment, which may be too lengthy, delaying necessary advancements in research and workforce development. This issue is also located in Section 2.
The language used for selecting stakeholders and subject matter experts is vague, lacking clear criteria, which may lead to accusations of favoritism or imbalanced representation. This concern is evident in Section 2.
There is no mechanism for accountability or evaluation of the effectiveness of the strategies and recommendations provided in the report, leading to potential issues in assessing their success. This is discussed in Section 2.
The amendment changes the funding period from '2020 through 2024' to '2025 through 2029' without justification, raising questions about the rationale behind this alteration. This is addressed in Section 2.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of the Act states its short title, which is “Congenital Heart Futures Reauthorization Act of 2024.”
2. National congenital heart disease research, surveillance, and awareness Read Opens in new tab
Summary AI
The Congenital Heart Futures Reauthorization Act of 2024 requires the Secretary to organize a workshop with experts to explore research gaps, workforce needs, and collaboration concerning adult congenital heart disease. Within three years, a report must be delivered to Congress with findings, recommendations for improving research and workforce capacity, and any progress on these strategies. Additionally, funding is extended from 2025 through 2029.
1. Short title Read Opens in new tab
Summary AI
The first section of the act states that it will be known as the “Congenital Heart Futures Reauthorization Act of 2024.”
2. National congenital heart disease research, surveillance, and awareness Read Opens in new tab
Summary AI
The section of the bill amends the Public Health Service Act to organize a workshop aimed at addressing needs and research related to congenital heart disease in adults, including care workforce issues and research gaps. It also requires a report on these efforts to Congress within three years and extends relevant authorizations through 2029.